Sure, that is an option.
Or just dilute to 150mm shares and run a P3 trial. Everyone just chills out for a while and see what happens. Even at 150mm shares, an oral disease-modifying pill for 50% of the AD population is worth more than a couple of shekels.
Or, find a partner. They'll value it as they would any P3-stage company with two promising pipeline candidates for major indications. Most likely the range is from $700mm - $3.5B. Do you think if Chris M offers a 50/50 revenue split for $3.5B there wouldn't be offers?
Or, as I jokingly suggested before, spend more money lobbying the FDA and politicians. Ultimately, politicians and regulators will respond to the people's wishes if the pressure is intense enough. That's why it would be nice to hear from the company what this would have cost had it been approved. When people realize they can take a pill for $7000 or an infusion for $30,000, the public demand increases and that pressure is often enough --- at least with the current administration's pay -to -play politics.
Or they could throw in the towel and give up as many here seem resigned will happen. I am not one of them. I didn't love the idea of going for it with a P2/3 pivotal trial and stellar but limited data. But here we are. I look forward, and I still see a lot of ballgame left to play. The stock price is what it is at any given time. The drug either works or it doesn't and worst case we find out in 2 or 3 more years. Best case we find out in April if the EMA has a change of heart. Still too early to say what happens. But if Dr. M goes, and he may, who specifically should replace him?
Market Data 
Markets 
